THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or maybe the participants are not able to tolerate the study drugs.88 These preclinical studies give paradigms for future clinical trials in AML, and